Back to discover
Disease

Glucagonoma

Active therapeutic pipelineEmerging research
MeSHGlucagonoma
1
Publications
12
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial with recent milestones (1 completed or reporting results).
Clinical Milestones1View
Results posted 1
Activity timeline1

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
12
All trials
1
Active
0
Late-stage
6
Completed
Recently completed

Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors

Phase 2 · Completed · University of Southern California

A Phase 2 Study of Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Phase 2 · Completed · Shaheen Shagufta

A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer

Phase 2 · Completed · National Cancer Institute (NCI)

Phase I Study of Anti-IGF-1R Monoclonal Antibody, IMC-A12, and mTOR Inhibitor, Everolimus, in Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Phase 1 · Completed · National Cancer Institute (NCI)

A Phase 2 Study of GW786034 (Pazopanib) in Advanced Low-Grade or Intermediate-Grade Neuroendocrine Carcinoma

Phase 2 · Completed · National Cancer Institute (NCI)

A Phase I Trial of Herceptin and Interleukin-12

Phase 1 · Completed · National Cancer Institute (NCI)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes5
  • Gastrinoma1
  • Glucagonoma1
  • Insulinoma1
  • Neuroendocrine Tumors1
  • Pancreatic Neoplasms1
Leading journals1
  • Journal of neuroendocrinology1
Leading researchers8
  • Bartsch DK1
  • Castaño JP1
  • Christ E1
  • Faggiano A1
  • Falconi M1
  • Hofland J1
  • Lamarca A1
  • Perren A1
Affiliations (unnormalised)6
  • Centre Hospitalier Annecy Genevois (CHANGE)1
  • Department of Clinical and Molecular Medicine1
  • Department of Oncology - OncoHealth Institute1
  • ENETS Centre of Excellence1
  • ENETS Centre of Excellence for Neuroendocrine and Endocrine Tumours1
  • Hospital Universitario Reina Sofía1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA.

Identifiers
MeSHGlucagonoma
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.